Upadacitinib monotherapy effective in refractory RA
Rheumatologists now have many choices for the treatment of such patients, expert says
Monotherapy with the JAK1-selective inhibitor upadacitinib is effective in patients with active rheumatoid arthritis who have an inadequate response to methotrexate, according to results of a phase 3 trial.
Researchers from 24 countries compared upadacitinib monotherapy to continuing methotrexate treatment in a randomised controlled trial of 648 rheumatoid arthritis patients with an inadequate response to methotrexate.
